Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Fate Therapeutics (NASDAQ:FATE) but lowered the price target from $8 to $5.
August 10, 2023 | 2:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Fate Therapeutics but lowered the price target from $8 to $5.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100